Belmont Medical Technologies Receives $221K in Training Grant via via the Commonwealth of Massachusetts’ Workforce Training Fund Program

March 17, 2021

Belmont Medical Technologies notes the grant funding was awarded via the Commonwealth of Massachusetts’ Workforce Training Fund Program.

Belmont Medical Technologies currently employs 187 associates, including 137 in Massachusetts.

The training plan made possible by this grant will focus on enhancing critical skills in the areas of Lean Principles, People Management, and Train the Trainer to further develop and sustain Operational Excellence at Belmont’s 56,000 square foot facility. The grant will be administered over a 2-year period and has been matched by Belmont.

Brian Ellacott, Chief Executive Officer, Belmont, stated “One of Belmont’s core values is to ’embrace learning and growth’. This grant award goes a long way to support our efforts in this area. We are grateful to be one of the grant recipients and remain committed to creating jobs in the Commonwealth of Massachusetts and to enhancing our employees’ skills”.

This project is funded by a Workforce Training Fund grant from the Commonwealth of Massachusetts, Executive Office of Labor and Workforce Development. The grant program is administered by Commonwealth Corporation.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy